CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
Aim. To compare cost-effectiveness of the use of direct factor Xa inhibitors rivaroxaban and apixaban in patients with non-valvular atrial fibrillation (AF) and to assess the impact of the both therapies on the healthcare budget of Russian Federation.Material and methods. Pharmacoeconomic analysis w...
Main Authors: | S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova |
---|---|
Format: | Article |
Language: | English |
Published: |
Stolichnaya Izdatelskaya Kompaniya
2017-03-01
|
Series: | Racionalʹnaâ Farmakoterapiâ v Kardiologii |
Subjects: | |
Online Access: | https://www.rpcardio.com/jour/article/view/1414 |
Similar Items
-
Comparison of peri-procedural anticoagulation with rivaroxaban and apixaban during radiofrequency ablation of atrial fibrillation
by: Jayasree Pillarisetti, et al.
Published: (2020-11-01) -
Non-valvular atrial fibrillation: impact of apixaban on patient outcomes
by: Ioannou A, et al.
Published: (2017-11-01) -
Efficacy and safety of new oral anticoagulants compared with warfarin in cardioembolic prophylaxis of patients with non valvular atrial fibrillation. More lights than shadows
by: Luca Masotti, et al.
Published: (2012-10-01) -
Direct oral anticoagulants for secondary prevention in patients with non-valvular atrial fibrillation
by: Luca Masotti, et al.
Published: (2013-12-01) -
Antithrombotic alternatives for stroke prevention in atrial fibrillation: critical differences and remaining questions
by: James S Kalus
Published: (2013-04-01)